Evidence map›Paper›PMID 33669778›Full record

ArticleJournal of clinical medicine2021

Associations of

Agnė Bartnykaitė, Aistė Savukaitytė, Rasa Ugenskienė, Monika Daukšaitė, Erika Korobeinikova, Jurgita Gudaitienė, Elona Juozaitytė

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Cell Segmentation as Strategic Decision Making.Research (Washington, D.C.) · 2026
    Article
  3. Article
  4. TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  5. Genetic Variations inCancers · 2025
    Article
  6. Personalized treatment approach for HER2-positive metastatic breast cancer.Medical oncology (Northwood, London, England) · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Agnė BartnykaitėOncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
Aistė SavukaitytėOncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
Rasa UgenskienėOncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
Monika DaukšaitėOncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
Erika KorobeinikovaDepartment of Oncology and Hematology, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, LT-50161 Kaunas, Lithuania.
Jurgita GudaitienėDepartment of Oncology and Hematology, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, LT-50161 Kaunas, Lithuania.
Elona JuozaitytėDepartment of Oncology and Hematology, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, LT-50161 Kaunas, Lithuania.
Lithuanian University of Health Sciences · LTHospital of Lithuanian University of Health Sciences Kaunas Clinics · LT

Funding

Lietuvos Mokslo Taryba 09.3.3-LMT-K-712Lietuvos Sveikatos Mokslų Universitetas 0101
6 · The paper itself

Abstract

Breast cancer is one of the most common cancers worldwide. Single nucleotide polymorphisms (SNPs) in

Indexed as

associationsbreast cancerMDM2MDM4SNP

Identifiers

PMID33669778
PMCPMC7922970
OpenAlexW3130346219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.